SecBot SecBot
PRESS-RELEASE ·Filed Apr 17, 2026

EVAX

Evaxion
BULLISH
Impact 7/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · Announcement
Actionable Insight ▲ Bullish

Traders should monitor upcoming three-year clinical data in H2 2026 and watch for potential partnership announcements, especially given the strong immune response correlation with AI predictions. This data strengthens EVAX's platform story, which may attract biotech interest despite small market cap.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$4.45
T+0 close · Apr 17, 2026 · via day close
Latest settled
−31.91%
T+60 · $3.03
Vs SPY
−38.05%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 17 $4.45entry
  2. T+1 · 7mo ago +0.90%α +1.09% · $4.49
  3. T+5 · 7mo ago −9.44%α −9.99% · $4.03
  4. T+20 · 6mo ago −7.42%α −12.79% · $4.12
  5. T+60 · 4mo ago −31.91%α −38.05% · $3.03
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Evaxion announced new Phase 2 data for its AI-designed personalized cancer vaccine EVX-01, showing 86% of vaccine targets triggered a tumor-specific immune response, a rate higher than previously reported methods. The data, to be presented at AACR, also show durable immune responses and de novo T-cell activation, reinforcing the predictive power of its AI-Immunology™ platform.

Key Facts

  • 86% of vaccine targets in EVX-01 triggered a tumor-specific immune response, a record-high rate
  • Durable de novo T-cell responses observed, with 86% of responses being novel tumor-specific T cells
  • Positive correlation between AI-prediction scores and immune response magnitude confirms platform accuracy
  • Phase 2 trial in advanced melanoma combines EVX-01 with KEYTRUDA® (pembrolizumab), showing 75% Objective Response Rate at two years
  • Three-year clinical data expected in H2 2026

Financial Impact

Potential re-rating of EVAX based on clinical validation of AI platform and vaccine efficacy; increases likelihood of partnership or licensing interest

market valuationpipeline valueplatform credibility

Risk Factors

  • Clinical outcomes may not improve proportionally despite strong immune response
  • High market expectations could lead to sell-off if H2 2026 data disappoints
  • Dilution risk given $35M market cap and likely need for future funding

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3276460

Track record

50 reports on EVAX

Performance horizon

6 of 10 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 9 of 10 went positive at some point.

Filters
  1. Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  2. Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  3. Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
  4. Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  5. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  6. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  7. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  8. Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
  9. Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
  10. Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
Showing 10 of 50

US Market Status

Market Closed · Opens in 6h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 17, 2026